A new trading day began on Tuesday, with Karyopharm Therapeutics Inc (NASDAQ: KPTI) stock price down -3.98% from the previous day of trading, before settling in for the closing price of $0.62. KPTI’s price has ranged from $0.58 to $1.70 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 56.57%. Meanwhile, its annual earnings per share averaged 45.03%. With a float of $116.47 million, this company’s outstanding shares have now reached $125.30 million.
Let’s determine the extent of company efficiency that accounts for 325 employees. In terms of profitability, gross margin is 95.68%, operating margin of -84.86%, and the pretax margin is -58.73%.
Karyopharm Therapeutics Inc (KPTI) Breakdown of a Key Holders of the stock
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Karyopharm Therapeutics Inc is 7.71%, while institutional ownership is 47.11%. The most recent insider transaction that took place on Feb 04 ’25, was worth 2,664. In this transaction President and CEO of this company sold 4,099 shares at a rate of $0.65, taking the stock ownership to the 1,120,158 shares. Before that another transaction happened on Jan 06 ’25, when Company’s President and CEO sold 4,055 for $0.78, making the entire transaction worth $3,175. This insider now owns 1,124,257 shares in total.
Karyopharm Therapeutics Inc (KPTI) Recent Fiscal highlights
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.26 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 45.03% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 24.25% during the next five years compared to 16.79% growth over the previous five years of trading.
Karyopharm Therapeutics Inc (NASDAQ: KPTI) Trading Performance Indicators
Here are Karyopharm Therapeutics Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 2.93. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 0.51.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.14, a number that is poised to hit -0.26 in the next quarter and is forecasted to reach -0.72 in one year’s time.
Technical Analysis of Karyopharm Therapeutics Inc (KPTI)
Looking closely at Karyopharm Therapeutics Inc (NASDAQ: KPTI), its last 5-days average volume was 0.88 million, which is a jump from its year-to-date volume of 0.79 million. As of the previous 9 days, the stock’s Stochastic %D was 20.08%. Additionally, its Average True Range was 0.05.
During the past 100 days, Karyopharm Therapeutics Inc’s (KPTI) raw stochastic average was set at 3.13%, which indicates a significant decrease from 6.38% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 54.76% in the past 14 days, which was lower than the 81.39% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.6984, while its 200-day Moving Average is $0.8483. However, in the short run, Karyopharm Therapeutics Inc’s stock first resistance to watch stands at $0.6303. Second resistance stands at $0.6626. The third major resistance level sits at $0.6827. If the price goes on to break the first support level at $0.5779, it is likely to go to the next support level at $0.5578. Now, if the price goes above the second support level, the third support stands at $0.5255.
Karyopharm Therapeutics Inc (NASDAQ: KPTI) Key Stats
With a market capitalization of 75.47 million, the company has a total of 126,191K Shares Outstanding. Currently, annual sales are 146,030 K while annual income is -143,100 K. The company’s previous quarter sales were 38,780 K while its latest quarter income was -32,070 K.
